tiprankstipranks
Trending News
More News >
Concord Medical Services (CCM)
:CCM

Concord Medical Services (CCM) AI Stock Analysis

Compare
103 Followers

Top Page

CC

Concord Medical Services

(NYSE:CCM)

Rating:39Underperform
Price Target:
$6.00
▲(3.45%Upside)
The overall stock score for Concord Medical Services is significantly impacted by its poor financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall stock score, highlighting considerable risk.

Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)

Concord Medical Services Business Overview & Revenue Model

Company DescriptionConcord Medical Services Holdings Limited (CCM) is a healthcare company that operates in the medical services sector, primarily focusing on providing specialty hospital management services and diagnostic imaging services. The company is based in China and is known for its extensive network of medical centers, which offer a wide range of services including radiotherapy, oncology, and diagnostic imaging. Concord Medical Services aims to enhance the quality of healthcare services in the regions it operates by leveraging advanced medical technologies and expertise.
How the Company Makes MoneyConcord Medical Services generates revenue through several key streams. The primary source of income is from its network of medical centers, which offer diagnostic imaging services such as MRI, CT scans, and other advanced imaging technologies. Additionally, the company earns money through providing radiotherapy and oncology services. Concord Medical also engages in hospital management services, where it partners with hospitals to manage their radiotherapy and diagnostic imaging departments, sharing revenue from these operations. These strategic partnerships and the growing demand for specialized medical services in China contribute significantly to its earnings.

Concord Medical Services Financial Statement Overview

Summary
Concord Medical Services faces severe financial difficulties, with significant revenue decline, negative gross and net profit margins, and a highly leveraged balance sheet. The company struggles with negative cash flows and relies unsustainably on external financing.
Income Statement
15
Very Negative
Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.
Balance Sheet
10
Very Negative
The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.
Cash Flow
20
Very Negative
Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue471.70M383.96M537.40M472.08M485.63M223.01M
Gross Profit-80.78M-79.16M-76.61M-152.41M-56.90M13.08M
EBITDA-326.79M-345.62M-344.16M-401.86M-363.86M-236.72M
Net Income-378.93M-308.24M-297.66M-489.66M-271.43M-309.99M
Balance Sheet
Total Assets6.62B6.73B6.05B6.00B6.23B5.33B
Cash, Cash Equivalents and Short-Term Investments326.90M350.85M58.14M158.28M157.39M334.26M
Total Debt3.56B3.93B3.30B3.24B2.73B2.35B
Total Liabilities4.70B5.11B4.31B3.99B3.49B2.93B
Stockholders Equity-2.14B-2.28B-2.12B-1.86B-1.37B-662.96M
Cash Flow
Free Cash Flow0.00-808.58M-392.17M-600.47M-1.12B-734.47M
Operating Cash Flow0.00-397.75M-276.47M-216.69M-359.31M-229.77M
Investing Cash Flow0.00-593.44M-47.68M-118.79M-565.98M-533.88M
Financing Cash Flow0.001.15B257.65M383.09M642.45M1.14B

Concord Medical Services Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.80
Price Trends
50DMA
6.82
Negative
100DMA
5.66
Positive
200DMA
5.67
Positive
Market Momentum
MACD
-0.35
Positive
RSI
43.08
Neutral
STOCH
52.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Neutral. The current price of 5.8 is below the 20-day moving average (MA) of 6.13, below the 50-day MA of 6.82, and above the 200-day MA of 5.67, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 52.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCM.

Concord Medical Services Risk Analysis

Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Concord Medical Services Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AMAMS
64
Neutral
$16.06M11.316.16%35.25%175.21%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
50
Neutral
$40.81M404.0093.38%11.77%2.33%
49
Neutral
$46.65M-951.52%-0.70%-2.38%
TOTOI
47
Neutral
$231.62M-227.77%17.64%13.86%
43
Neutral
$45.85M-131.17%9.79%-47.01%
CCCCM
39
Underperform
$25.18M14.03%-29.82%-2.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCM
Concord Medical Services
5.80
-3.51
-37.70%
AMS
American Shared Hospital Services
2.49
-0.69
-21.70%
MODV
ModivCare
3.25
-21.82
-87.04%
CCEL
Cryo-Cell International
5.05
-1.83
-26.60%
TOI
Oncology Institute
2.52
2.04
425.00%
PIII
P3 Health Partners
6.38
-18.62
-74.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 17, 2025